GENEVA, Oct 22 (KUNA) -- Novartis, based in Basel, said Monday that Voltaren Gel 1% has received US regulatory approval as the first topical prescription treatment that patients can apply directly to sites of pain associated with osteoarthritis.
Osteoarthritis is a chronic condition characterized by the breakdown of cartilage in the joint. Cartilage cushions the ends of the bones in joints - such as knees, hands, elbows, wrists, ankles and feet - which allows for easy movement.
When cartilage erodes, bones can rub together, resulting in pain and loss of free movement in the joint.
The most common symptoms include pain, joint soreness, stiffness and deterioration of overall coordination, posture and walking.
Arthritis and related conditions, such as Osteoarthritis, cost the US economy nearly USD 128 billion per year in medical care and indirect expenses, including lost wages and production.